Observational studyMedicine2026
Cardiac remodeling in CKD: Diagnostic utility of circulating fibroblast growth factor‑23.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left ventricular hypertrophy (LVH) is a hallmark of uremic cardiomyopathy and a strong predictor of adverse outcomes in chronic kidney disease (CKD). Conventional biomarkers often fail to capture the full spectrum of risk, highlighting the need for novel predictors. Fibroblast growth factor‑23 (FGF‑23) has been implicated in pathological cardiac remodeling through FGFR4‑dependent signaling pathways. This study aimed to evaluate the diagnostic utility of circulating FGF‑23 for cardiac remodeling, particularly Left ventricular hypertrophy, in non‑dialysis CKD patients. A cross‑sectional observational study was conducted between October 2024 and April 2025 in Thi‑Qar, Iraq. Participants included 89 patients with CKD stage 3 to 5, 40 patients with heart failure, and 37 healthy controls. Demographic, clinical, biochemical, and echocardiographic data were collected. Serum FGF‑23 was measured using enzyme-linked immunosorbent assay. Associations with cardiac remodeling were assessed using logistic regression models with sequential adjustments. Diagnostic performance was evaluated by receiver operating characteristic curve analysis. Serum FGF‑23 was significantly higher in CKD and heart failure groups compared to controls. Among CKD patients, FGF‑23 levels were elevated in those with cardiac remodeling (164.9 vs 133.4 pg/mL). Receiver operating characteristic analysis yielded an area under the curve of 0.723, with an optimal cutoff of >164.8 pg/mL (sensitivity, 50.9%; specificity, 96.7%). Multivariate regression confirmed FGF-23 as an independent risk factor for remodeling across all adjustment models (odds ratio range, 1.021-1.039; P < .01). Circulating FGF-23 is independently associated with cardiac remodeling in non-dialysis CKD patients. Its high specificity suggests potential utility as a biomarker for cardiovascular risk stratification, complementing traditional measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.